Ultragenyx Pharmaceutical Inc

RARE

Equity

ISIN US90400D1081 / Valor 22860122

NASDAQ (2024-09-17)

USD 58.49-1.47%

Ultragenyx Pharmaceutical Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for rare and ultra-rare genetic diseases. The company's portfolio includes products such as DOJOLVI® for long-chain fatty acid oxidation disorders and CRYSVITA® for X-linked hypophosphatemia and tumor-induced osteomalacia. Ultragenyx is dedicated to providing patients with life-changing therapies that address unmet medical needs in the rare disease community.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenues

Ultragenyx Pharmaceutical Inc. reported $109 million in total revenue for the first quarter of 2024, which represents an 8% growth compared to the same period in 2023.

Operating Expenses

Total operating expenses for the first quarter of 2024 were $274 million, including non-cash stock-based compensation of $37 million.

Net Loss

For the first quarter of 2024, Ultragenyx Pharmaceutical Inc. reported a net loss of $171 million, or $2.03 per share basic and diluted, compared with a net loss for the first quarter of 2023 of $164 million, or $2.33 per share, basic and diluted.

Net Cash Used in Operations and Cash Balance

Net cash used in operations for the quarter ended March 31, 2024, was $191 million.

2024 Financial Guidance

For the full year 2024, Ultragenyx Pharmaceutical Inc. reaffirms its total revenue guidance in the range of $500 million to $530 million, with Crysvita revenue expected to be between $375 million to $400 million and Dojolvi revenue between $75 million to $80 million.

Summarized from source with an LLMView Source

Key figures

55.2%1Y

-40.5%3Y

32.3%5Y

Performance

49.7%1Y

51.8%3Y

55.4%5Y

Volatility